Literature DB >> 7816891

Nicotine self-administration and locomotor activity are not modified by the 5-HT3 antagonists ICS 205-930 and MDL 72222.

W A Corrigall1, K M Coen.   

Abstract

The subtype-selective serotonin 5-HT3 antagonists MDL 72222 and ICS 205-930 were tested for their ability to modify nicotine self-administration and locomotor activity in rats. In self-administration experiments, MDL 72222 produced no statistically significant changes over a dose range of 1 to 30 micrograms/kg, nor at the considerably higher dose of 1 mg/kg. MDL 72222 was similarly without effect in nicotine-produced locomotor activity, except at the 1 mg/kg dose, which reduced scores. In an initial test on nicotine self-administration, ICS 205-930 produced a small decrease in drug-taking behavior at 1 and 3 micrograms/kg which just reached statistical significance, but had no effects at higher doses. However, these low-dose effects could not be replicated. In addition, ICS 205-930 was without effect on nicotine locomotor activity, even at the two low doses that had reduced self-administration. We conclude that these 5-HT3 antagonists do not modulate nicotine reinforcement or behavioral arousal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7816891     DOI: 10.1016/0091-3057(94)90457-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  16 in total

1.  The role of nicotinic acetylcholine receptors in the primary reinforcing and reinforcement-enhancing effects of nicotine.

Authors:  Matthew I Palmatier; Xiu Liu; Anthony R Caggiula; Eric C Donny; Alan F Sved
Journal:  Neuropsychopharmacology       Date:  2006-11-08       Impact factor: 7.853

Review 2.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 3.  A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.

Authors:  R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman
Journal:  Int Rev Neurobiol       Date:  2016-03-21       Impact factor: 3.230

Review 4.  Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.

Authors:  Tina K Machu
Journal:  Pharmacol Ther       Date:  2011-02-26       Impact factor: 12.310

5.  Dissociating the primary reinforcing and reinforcement-enhancing effects of nicotine using a rat self-administration paradigm with concurrently available drug and environmental reinforcers.

Authors:  Matthew I Palmatier; F Fay Evans-Martin; Alycia Hoffman; Anthony R Caggiula; Nadia Chaudhri; Eric C Donny; Xiu Liu; Sherri Booth; Maysa Gharib; Laure Craven; Alan F Sved
Journal:  Psychopharmacology (Berl)       Date:  2005-10-25       Impact factor: 4.530

6.  Defining the putative inhibitory site for a selective negative allosteric modulator of human α4β2 neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Tatiana F González-Cestari; Bitna Yi; Ryan E Pavlovicz; R Thomas Boyd; Chenglong Li; Stephen C Bergmeier; Dennis B McKay
Journal:  ACS Chem Neurosci       Date:  2012-05-25       Impact factor: 4.418

7.  Adolescent-onset nicotine self-administration modeled in female rats.

Authors:  Edward D Levin; Amir H Rezvani; Daniel Montoya; Jed E Rose; H Scott Swartzwelder
Journal:  Psychopharmacology (Berl)       Date:  2003-05-23       Impact factor: 4.530

Review 8.  The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.

Authors:  E A Engleman; Z A Rodd; R L Bell; J M Murphy
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

9.  Enhanced alcohol-seeking behavior by nicotine in the posterior ventral tegmental area of female alcohol-preferring (P) rats: modulation by serotonin-3 and nicotinic cholinergic receptors.

Authors:  Sheketha R Hauser; Gerald A Deehan; Jamie E Toalston; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Psychopharmacology (Berl)       Date:  2014-03-06       Impact factor: 4.530

10.  5HT3 receptor antagonists do not block nicotine induced hyperactivity in rats.

Authors:  B Arnold; K Allison; S Ivanová; P R Paetsch; T Paslawski; A J Greenshaw
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.